Looking up: Recent advances in understanding and treating peritoneal carcinomatosis

LA Lambert - CA: a cancer journal for clinicians, 2015 - Wiley Online Library
Answer questions and earn CME/CNE Until recently, a diagnosis of peritoneal
carcinomatosis was uniformly accompanied by a grim prognosis that was typically measured …

The use of intraperitoneal chemotherapy for gastric malignancies

A Macrì, F Morabito - Expert Review of Anticancer Therapy, 2019 - Taylor & Francis
Introduction: Gastric cancer is the fourth/fifth most common malignancy worldwide, with only
a quarter of patients achieving a 5-year survival rate. It has been estimated that 15–50% or …

[HTML][HTML] Prognostic factors and recurrence patterns in T4 gastric cancer patients after curative resection

BY Zhu, SQ Yuan, RC Nie, SM Li, LR Yang… - Journal of …, 2019 - ncbi.nlm.nih.gov
Background: To investigate prognostic factors and recurrence patterns in T4 gastric cancer
(GC) patients after curative resection. Methods: Between January 2004 and December …

Malignant ascites supernatant enhances the proliferation of gastric cancer cells partially via the upregulation of asparagine synthetase

Y Jiao, X Peng, Y Wang, Z Hao, L Chen… - Oncology …, 2023 - spandidos-publications.com
Malignant ascites (MA) is a common manifestation of advanced gastric cancer (GC) with
peritoneal metastasis (PM), which usually indicates a poor prognosis. The present study …

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for colorectal peritoneal metastases: Analysis of short-and long-term outcomes

F Rosa, F Galiandro, R Ricci, D Di Miceli… - … archives of surgery, 2021 - Springer
Background Peritoneal metastases carry the worst prognosis among all sites of colorectal
cancer (CRC) metastases. In recent years, the advent of cytoreductive surgery (CRS) and …

[HTML][HTML] A narrative review of intraperitoneal chemotherapy and cytoreductive surgery (CRS) for peritoneal metastases in gastric cancer

T Boerner, P Piso - Journal of Gastrointestinal Oncology, 2021 - ncbi.nlm.nih.gov
Peritoneal carcinomatosis of gastric origin is an aggressive tumor entity. Historically it has
been considered a terminal disease with no long-term survival, due to limited therapeutic …

Hyperthermic Intraperitoneal Chemotherapy in the Management of Gastric Cancer: A Narrative Review

M Mazurek, M Szlendak, A Forma, J Baj… - International Journal of …, 2022 - mdpi.com
Gastric cancer (GC) patients with peritoneal metastasis tend to achieve poor clinical
outcomes. Until recently, the treatment options were limited mainly to either palliative …

Risk predictors for adverse outcome in pediatric febrile neutropenia: single center experience from a low and middle-income country

M Prasad, G Chinnaswamy, B Arora, T Vora… - Indian Journal of …, 2014 - journals.lww.com
BACKGROUND: Risk stratification of patients with febrile neutropenia (FN) into those at"
High Risk" and" Low Risk" of developing complications helps in making decisions regarding …

Hyperthermic intraperitoneal chemotherapy and cytoreductive surgery in the management of peritoneal carcinomatosis

R Rajeev, KK Turaga - Cancer Control, 2016 - journals.sagepub.com
Background Malignant peritoneal disease can lead to significant debility due to bowel
obstructions, ascites, and cancer cachexia. Moreover, inadequate imaging techniques can …

Cytoreductive surgery combined with hyperthermic intraperitoneal chemoperfusion for the treatment of gastric cancer: A single-centre retrospective study

Y Tu, Y Tian, Z Fang, Q Ruan, H Tang… - International Journal …, 2016 - Taylor & Francis
Aim: Cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal
chemoperfusion (HIPEC) is the treatment regime most likely to achieve prolonged survival in …